Replies to post #228435 on Biotech Values

[DewDiligence]

CNAT reverse-merger CC had no Q&A session. What a lame way to get started!

[DewDiligence]

Histogen/CNAT pursuing androgenetic alopecia:

https://www.globenewswire.com/news-release/2020/05/11/2031027/0/en/Histogen-Receives-US-FDA-IND-Approval-to-Initiate-Phase-1b-2a-Trial-of-HST-001-in-Androgenic-Alopecia.html

HST 001, or Hair Stimulating Complex (HSC), is intended to be a physician-administered therapeutic for hair loss. HSC is anticipated to be a safe, minimally-invasive treatment that promotes new hair growth where existing treatments only reduce hair loss. HSC is manufactured to enrich for growth factors including KGF, VEGF, and follistatin, which are involved in signaling stem cells in the body, and have been shown to be important in hair formation and the stimulation of resting hair follicles.

Good luck with that, LOL.

The ticker symbol will change to HSTO when the reverse-merger with CNAT closes.

[DewDiligence]

CNAT now trading as HSTO—following reverse-merger and 1:10 reverse split:

https://www.globenewswire.com/news-release/2020/05/27/2039308/0/en/Histogen-Announces-Successful-Completion-of-its-Merger-with-Conatus-Pharmaceuticals.html

The company’s lead program is in androgenetic alopecia (#msg-155555588).